ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $124.395 million which missed the analyst consensus estimate of $131.658 million by 5.52 percent. This is a 1.98 percent increase over sales of $121.984 million the same period last year.